Moolec Science SA Ordinary Shares and Pharming Group N.V. ADS, each representing 10 ordinary shares
Moolec Science SA, a science-based ingredient company, engages in developing ingredients for food, pet food, animal feed, and dietary supplements using molecular farming technology in Cayman Islands and internationally. It produces animal proteins in plants to heal the meat production system. The company is based in Grand Cayman, Cayman Islands.
Open MLEC dashboard ↗Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
Open PHAR dashboard ↗You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.
Sign in →